ANSWER: B

Rationale:

Volume of distribution (Vd) is calculated as Vd = Dose / C for a single-compartment model after IV bolus injection, where C is the extrapolated plasma concentration at time zero. It is a mathematical proportionality constant — not a real anatomical volume — that relates the total amount of drug in the body to the concentration measured in plasma. Its power lies in interpretation: comparing Vd to known physiological fluid volumes provides mechanistic insight into drug distribution. Reference volumes: plasma 3–4 L (drugs confined to plasma: heparin, large proteins); interstitial fluid 12 L; extracellular fluid = plasma + interstitial 15 L (drugs like aminoglycosides); total body water 42 L (drugs like ethanol); intracellular fluid alone 27 L. A Vd of 700 L (10 L/kg) far exceeds any anatomical compartment in the body — the only explanation is that the drug is avidly sequestered in peripheral tissues (bound to tissue proteins, accumulated in lipid compartments, or trapped intracellularly), leaving very low plasma concentrations relative to total body drug. Drugs with very large Vd include chloroquine (~200–800 L), amiodarone (~5,000 L), digoxin (~500 L), and tricyclic antidepressants (~1,000+ L). Clinical implications of large Vd: (1) Long half-life (t½ = 0.693 × Vd / CL); (2) Not removable by hemodialysis (most drug is in tissues, not plasma); (3) Large loading doses required to rapidly achieve therapeutic concentrations (LD = Vd × Css); (4) Drug-overdose management is challenging because tissue-bound drug continuously redistributes into plasma after drug removal. Option A misidentifies the Vd formula and incorrectly interprets large Vd as indicating plasma confinement — it is actually the reverse. Option C is incorrect — Vd of 700 L cannot be explained by protein binding alone; protein binding affects the free drug fraction in plasma but does not produce a Vd of 700 L if the drug only distributes into body water. Option D provides an incorrect formula and incorrect interpretation. Option E is incorrect — large Vd is not associated with exclusive renal elimination; in fact, drugs with very large Vd (amiodarone, chloroquine) are primarily eliminated hepatically; water-soluble renally eliminated drugs typically have small Vd.

ANSWER: B

Rationale:

Plasma protein binding is a reversible, saturable, and clinically consequential pharmacokinetic phenomenon. The two principal drug-binding plasma proteins are: (1) Albumin (molecular weight 66.5 kDa, plasma concentration 35–50 g/L) — the most abundant plasma protein, primarily binds acidic drugs (NSAIDs, sulfonamides, penicillins, warfarin, furosemide, phenytoin) and some neutral/lipophilic drugs at two main binding sites (Sudlow site I — binds bulky heterocyclic anions like warfarin, phenytoin; Sudlow site II — binds aromatic carboxylic acids like ibuprofen, valproate). (2) Alpha-1-acid glycoprotein (AGP, orosomucoid, molecular weight 44 kDa, plasma concentration 0.6–1.2 g/L) — an acute phase protein primarily synthesized by the liver that binds basic drugs and cationic lipophilic molecules (propranolol, lidocaine, quinidine, chlorpromazine, methadone, tricyclic antidepressants). AGP concentrations increase substantially during acute-phase responses (surgery, myocardial infarction, infection, cancer), increasing binding of basic drugs and reducing their free fraction and pharmacological effect. The pharmacokinetic consequence of protein binding: only the unbound (free) drug fraction (fu) crosses biological membranes and is available for tissue distribution, receptor binding, hepatic metabolism, and glomerular filtration. Higher protein binding (lower fu) reduces the apparent Vd because less free drug is available to distribute into tissues — drug is retained in the plasma compartment. Free drug fraction: fu = Cfree / Ctotal; for a drug that is 99% protein-bound, fu = 0.01 — only 1% of total plasma drug is pharmacologically active. Option A reverses the protein-drug type assignments — albumin primarily binds acidic drugs, AGP primarily binds basic drugs. Option C incorrectly identifies transferrin as a drug-binding protein (transferrin primarily transports iron) and incorrectly states protein binding has no effect on Vd. Option D is incorrect — IgG immunoglobulins are not primary drug-binding proteins; protein binding reduces, not increases, apparent Vd. Option E is incorrect — AGP does not bind all drugs with equal affinity; it has preferential affinity for basic/cationic drugs; albumin is a major drug-binding protein.

ANSWER: C

Rationale:

Interpreting Vd values by comparison to known physiological fluid compartments is one of the most clinically useful applications of pharmacokinetic principles. The key reference volumes in a 70 kg adult are: plasma 3–4 L (0.04–0.05 L/kg); interstitial fluid 12–15 L; extracellular fluid (ECF = plasma + interstitial) 15–18 L (0.2–0.25 L/kg); total body water (TBW) 42 L (0.6 L/kg); intracellular fluid 27 L. A Vd of 25 L falls squarely within the extracellular fluid compartment range. Drugs with Vd approximating ECF typically share the following characteristics: polar/hydrophilic nature preventing passive transcellular membrane crossing; maintained predominantly in ionized form at physiological pH (preventing passive diffusion into cells); and/or large molecular size limiting transcellular passage. The aminoglycoside antibiotics are the classic clinical example: gentamicin, tobramycin, and amikacin all have Vd approximately 0.2–0.3 L/kg (~14–21 L in 70 kg adults) — they distribute throughout the extracellular space but are excluded from intracellular fluid by their polycationic, hydrophilic nature. This has important clinical implications: (1) Aminoglycoside doses must be weight-based and adjusted for conditions altering ECF volume (edema, ascites — increasing Vd and requiring higher loading doses); (2) Once-daily extended-interval dosing is based partly on the rapid initial distribution phase; (3) Aminoglycosides accumulate in proximal tubular cells and cochlear hair cells through specific uptake mechanisms (megalin), but this intracellular accumulation is pharmacokinetically distinct from Vd (it occurs in specific tissues with very slow equilibration). Option A is incorrect — TBW is approximately 42 L, not 25 L; lipophilic drugs distributing into TBW typically have Vd of 0.5–0.7 L/kg. Option B is incorrect — plasma volume is only 3–4 L; a Vd of 25 L indicates distribution well beyond the vasculature. Option D is incorrect — intracellular fluid alone is approximately 27 L; drugs that preferentially accumulate intracellularly have Vd much larger than TBW (e.g., chloroquine, Vd >200 L/kg). Option E is incorrect — erythrocyte volume is approximately 2 L; a Vd of 25 L cannot be attributed primarily to red blood cell binding.

ANSWER: E

Rationale:

The two-compartment model is a pharmacokinetic abstraction that captures the common observation that drug distribution is not instantaneous — some tissues equilibrate with plasma rapidly (highly perfused organs: heart, brain, kidney, liver — the "central compartment"), while others equilibrate more slowly (muscle, skin, fat, bone — the "peripheral compartment"). After IV bolus injection, the plasma concentration-time profile shows a characteristic biphasic decline on a semi-logarithmic plot: (1) Alpha () distribution phase — the initial, steeper segment reflecting rapid drug redistribution from the central compartment (plasma and highly perfused organs) into the peripheral compartment; during this phase, the rate of drug transfer to peripheral tissues greatly exceeds the rate of elimination; plasma concentrations fall steeply because drug is both being eliminated AND being distributed away from plasma. (2) Beta () elimination phase — the later, shallower segment reflecting drug elimination from the central compartment while the system is in pseudo-distribution equilibrium; as drug leaves the central compartment by elimination, drug in the peripheral compartment continuously re-equilibrates back into plasma; the terminal half-life (t½) reflects the overall elimination half-life of the drug in the post-distribution steady state. Clinical importance: the distinction between distribution and elimination phases matters for: (1) Toxicity immediately after IV bolus — if a drug distributes rapidly to CNS or heart (both in central compartment), early high plasma concentrations predict CNS or cardiac toxicity during the alpha phase even before peak effect-site concentration at peripheral organs (e.g., lidocaine CNS toxicity, digoxin cardiac toxicity); (2) Sampling timing for TDM — trough concentrations must be measured after distribution equilibrium is reached (in the beta phase), not during the alpha phase, to avoid misleadingly high readings; (3) Duration of action — redistribution from peripheral to central compartment after discontinuation can prolong drug effect (thiopental, as described in Question 11). Option A is incorrect — the two-compartment model produces a biphasic (biexponential), not monoexponential, plasma concentration decline. Option C is incorrect — the alpha and beta phases do not correspond to first-pass metabolism and renal elimination respectively; both hepatic and renal elimination contribute to the beta phase clearance term. Option D is incorrect — the peripheral compartment acts as a drug sink during distribution, not a supplementary source; plasma concentrations fall more steeply initially in a two-compartment vs one-compartment model. Option E is incorrect — the peripheral compartment is not limited to adipose tissue; it mathematically represents any tissue that equilibrates slowly with plasma.

ANSWER: B

Rationale:

The blood-brain barrier is the most pharmacologically restrictive vascular barrier in the human body, and understanding its molecular architecture explains why most systemically administered drugs fail to achieve therapeutic CNS concentrations and why CNS drug development remains one of the most challenging areas of pharmaceutical science. The BBB is formed by a specialized neurovascular unit comprising brain capillary endothelial cells, pericytes, astrocyte end-feet, and the basement membrane. The critical structural features of BBB endothelial cells that create pharmacokinetic restriction are: (1) Continuous tight junctions — claudin-5, occludin, and zonula occludens (ZO) proteins form extraordinarily impermeable cell-cell seals that eliminate the paracellular aqueous route available in peripheral capillaries; water-soluble, polar, and ionized drugs that in peripheral tissues can move between endothelial cells are blocked at the BBB. (2) Minimal transcytosis — unlike peripheral endothelium, BBB endothelial cells have very few pinocytotic vesicles, limiting transcellular vesicular transport of macromolecules. (3) Luminal P-gp and BCRP efflux — these ABC transporters on the blood-facing surface of the endothelium actively pump substrate drugs that have entered the cell back into the blood, creating an active defense against drug CNS penetration; clinically this means many drugs with adequate lipophilicity to passively enter the endothelial cell are still prevented from reaching the brain parenchyma (e.g., many antiretrovirals, anticancer drugs, antibiotics). (4) Drug-metabolizing enzymes — cytochromes (CYP1A1, CYP1B1), MAO, and conjugating enzymes within BBB endothelial cells inactivate some drugs intracellularly. Properties that favor BBB penetration: logP 1–4 (moderate lipophilicity — too lipophilic and P-gp efflux becomes significant), MW <400–500 Da, low hydrogen bond count, predominantly unionized at physiological pH, low plasma protein binding (only free drug distributes), not a P-gp/BCRP substrate. Options A, C, D, and E all contain fundamental anatomical or mechanistic errors about the BBB structure or function as described.

ANSWER: C

Rationale:

CNS drug penetration is determined by the interplay between passive transcellular permeability (governed by physicochemical properties) and active efflux (governed by transporter substrate status). The optimal physicochemical profile for BBB penetration combines: (1) Low molecular weight (<400–500 Da) — large molecules are sterically excluded from passive membrane diffusion and typically cannot use the limited transcytotic pathway efficiently; (2) Moderate lipophilicity (logP 1–4) — lipophilicity enables membrane partitioning (the rate-determining step for passive transcellular diffusion across the lipid bilayer); however, the relationship is not linear — very high logP (>4–5) increases P-gp efflux substrate probability and increases non-specific tissue binding and plasma protein binding, paradoxically reducing CNS penetration despite high membrane partitioning; (3) Predominantly unionized at physiological pH 7.4 — the unionized form is membrane-permeable; for weak acids with pKa << 7.4, the ionized fraction predominates in plasma; for weak bases with pKa >> 7.4, the ionized (protonated) form predominates; optimal CNS drugs have pKa values that keep them largely unionized at pH 7.4 (very weak acids or very weak bases); (4) Low plasma protein binding — only the unbound (free) drug fraction is available to cross the BBB; highly protein-bound drugs (99%) have 100-fold less free drug available for brain penetration than unbound drugs; (5) Not a P-gp or BCRP substrate — even drugs with excellent physicochemical properties for passive transcellular diffusion are actively returned to the circulation by luminal P-gp/BCRP if they are substrates; this is why many CNS-acting drugs required medicinal chemistry optimization to reduce P-gp recognition. Option A describes the antithesis of CNS-penetrant drugs — this profile (high MW, polar, ionized, P-gp substrate) describes drugs specifically designed to have minimal CNS penetration. Option B is incorrect — high plasma protein binding and negative logP are incompatible with CNS penetration; these properties ensure the drug remains in the plasma compartment. Option D is incorrect — extremely high lipophilicity (logP > 5–6) actually impairs CNS penetration due to increased P-gp efflux substrate recognition, poor aqueous solubility limiting drug concentration available for absorption, and excessive plasma protein binding reducing free drug fraction. Option E is incorrect — aquaporins transport water and small neutral molecules, not drugs; hydrophilicity reduces BBB penetration.

ANSWER: C

Rationale:

The thiopental redistribution paradigm is one of the most instructive and frequently cited illustrations of the two-compartment pharmacokinetic model applied to clinical drug behavior. Thiopental has the following key pharmacokinetic properties: high lipophilicity (logP ~2.0 for the thiolactone form at physiological pH) enabling rapid CNS penetration; pKa 7.6 — at physiological pH 7.4, approximately 61% is in the unionized form available for membrane diffusion; Vd approximately 2.3 L/kg (161 L in 70 kg adult) — large due to extensive tissue binding; protein binding approximately 85%; elimination half-life approximately 12 hours (hepatic oxidative metabolism). After IV bolus: thiopental rapidly distributes from plasma into highly perfused tissues including the brain (which receives approximately 15% of cardiac output despite being only 2% of body mass) — CNS concentrations rise to anesthetic levels within 30 seconds (one arm-brain circulation time). As plasma concentration falls due to ongoing distribution and some elimination, blood-brain concentration gradient reverses: thiopental now moves back from brain into blood, and simultaneously from blood into larger-volume, less-well-perfused compartments (skeletal muscle, then slowly adipose tissue). The net effect is redistribution of thiopental from brain to peripheral tissues — brain concentrations fall below the threshold for unconsciousness within 5–10 minutes even though total body elimination is minimal during this period. This redistribution-based termination of effect is exploited clinically: (1) Thiopental produces brief surgical anesthesia suitable for induction; (2) With repeated doses or infusion, peripheral compartments saturate — redistribution from brain becomes ineffective because concentration gradients equilibrate — and duration of action becomes determined by elimination half-life, producing very prolonged sedation after multiple doses (context-sensitive half-time increases with infusion duration). The redistribution principle also explains termination of action of other lipophilic drugs: propofol, fentanyl (early redistribution phase), midazolam. Option A is incorrect — thiopental is not significantly metabolized by plasma cholinesterases; it undergoes slow hepatic oxidation; the 12-hour elimination half-life is a real property of the parent drug, not inactive metabolites. Option B is incorrect — thiopental has a relatively large Vd (~2.3 L/kg), not small; and the offset is not primarily due to first-order elimination during the 5–10 minute window. Option D is incorrect — GABA-A receptor downregulation does not occur on the 5–10 minute timescale; redistribution, not tachyphylaxis, explains the rapid offset. Option E describes a plausible theoretical mechanism (ion trapping) but it is not the primary pharmacokinetic explanation — redistribution is the established and dominant mechanism.

ANSWER: C

Rationale:

Placental drug transfer is pharmacokinetically similar to transfer across other biological membranes — the same physicochemical principles that govern intestinal absorption and BBB penetration apply to the syncytiotrophoblast layer of the human placenta. The principal mechanism is passive transcellular diffusion, governed by Fick's law: lipophilicity (logP), molecular size, ionization state at physiological pH, and free drug fraction collectively determine the rate and extent of fetal drug exposure. Drug properties that FAVOR placental transfer: high lipophilicity (logP > 1–2), small molecular weight (<500 Da), low plasma protein binding (high fu), predominantly unionized form at pH 7.4. Drug properties that LIMIT placental transfer: high molecular weight (>1000 Da — macromolecules like heparin, insulin, large proteins), high plasma protein binding, highly ionized form at physiological pH, being a substrate of placental efflux transporters. The human placenta expresses P-glycoprotein (ABCB1) on the apical (fetal-facing, brush border) surface of syncytiotrophoblasts — effluxing substrates back toward the maternal circulation and providing partial fetal protection against some drugs (digoxin, some antiretrovirals). BCRP (ABCG2) is also expressed at the placenta. Despite these protective mechanisms, the clinical reality is that virtually all low-molecular-weight drugs used in clinical practice cross the placenta to some degree — the PLLR (FDA Pregnancy and Lactation Labeling Rule) framework and global pregnancy registries exist precisely because fetal exposure to most drugs must be disclosed and managed, not assumed to be zero. Classic examples: thalidomide (highly teratogenic, crosses placenta readily — lipophilic, MW 258); alcohol (ethanol, MW 46, highly lipophilic — freely crosses placenta causing fetal alcohol spectrum disorders); morphine (crosses placenta, causes neonatal opioid withdrawal); warfarin (MW 308, crosses placenta causing fetal warfarin syndrome in first trimester — hence heparin is used as the anticoagulant of choice in pregnancy). Option A is incorrect — passive diffusion is the primary mechanism for most drugs; active transport plays a secondary role. Option B is incorrect — the placenta is not an impermeable barrier; most clinically used drugs cross it. Option D is incorrect — MW is one factor among several; the 200 Da cutoff is not the sole determinant; lipophilicity and protein binding are also critical. Option E describes a completely fabricated mechanism — ionized drugs are less able, not more able, to cross membranes.

ANSWER: D

Rationale:

The loading dose is a pharmacokinetic strategy to rapidly achieve a target plasma concentration when waiting for steady state through multiple maintenance doses would be clinically unacceptable. The formula derives directly from the definition of Vd: Vd = Amount of drug in body / Plasma concentration. At the target steady-state concentration (Css): Amount of drug needed = Css × Vd. For IV administration: LD = Css × Vd. For oral administration (accounting for bioavailability): LD = (Css × Vd) / F. The loading dose depends on Vd, not clearance (CL determines the maintenance dose through Css = Dose rate / CL). Pharmacokinetic rationale for loading doses: without a loading dose, a drug reaches steady-state plasma concentrations after approximately 4–5 half-lives of maintenance dosing. For a drug with a half-life of 40 hours (e.g., digoxin), waiting 5 half-lives = 200 hours (approximately 8 days) before therapeutic concentrations are achieved is clinically unacceptable when treating rapid atrial fibrillation with hemodynamic compromise. A loading dose of LD = Css × Vd delivers the total amount of drug the body needs at steady state in a single (or divided) dose. Drug-specific examples: Digoxin (Vd ~500 L, t½ ~36–48 hours): LD 10–15 mcg/kg IV to rapidly achieve therapeutic range; Amiodarone (Vd ~5,000 L, t½ ~40–55 days): requires massive loading doses (typically 150–300 mg IV bolus + 900 mg over 24 hours + oral loading for weeks) due to enormous Vd; Vancomycin (loading dose based on actual body weight × target Css); Phenytoin (Vd ~0.5–0.7 L/kg, t½ ~22 hours). Loading doses are NOT needed (or are minimal) when: the drug has a short half-life (Css is achieved within hours without loading); the drug has a small Vd (maintenance doses rapidly fill the distribution volume). Option A provides the maintenance dose formula, not the loading dose formula. Option C incorrectly states that loading doses are for short half-life drugs — it is long half-life drugs that most critically need loading doses. Option D is incorrect — loading dose = Css × Vd, not Css × t½; these are entirely different parameters. Option E is incorrect — the first maintenance dose is not pharmacokinetically equivalent to a loading dose; for a drug with Vd = 350 L and Css target of 1 mg/L, LD = 350 mg, whereas a typical maintenance dose might be 50–100 mg.

ANSWER: A

Rationale:

Enterohepatic recirculation (EHR) is a pharmacokinetically important cycle that involves the complete anatomical and molecular pathway described in Option B. The key molecular steps are: (1) Hepatic Phase II conjugation — primarily glucuronidation by UDP-glucuronosyltransferases (UGT1A1, UGT1A4, UGT2B7) generates polar, water-soluble conjugates; (2) Biliary secretion by MRP2 (Multidrug Resistance Protein 2, ABCC2) — the canalicular membrane transporter that recognizes glucuronide and sulfate conjugates (as well as glutathione conjugates and some unconjugated amphiphilic drugs) and actively secretes them into bile; molecular weight >400 Da and anionic character are features that favor biliary secretion; (3) Intestinal bacterial deconjugation — the gut microbiome (particularly Bacteroidetes and Firmicutes expressing -glucuronidases and sulfatases) cleaves the glucuronide/sulfate conjugate, regenerating the lipophilic aglycone (parent drug); this step requires an intact gut microbiome — broad-spectrum antibiotics that disrupt EHR can alter the pharmacokinetics of EHR-dependent drugs; (4) Colonic reabsorption — the regenerated lipophilic parent drug crosses the colonic epithelium by passive diffusion and re-enters the portal circulation; (5) Return to systemic circulation. The pharmacokinetic consequences: multiple plasma concentration peaks on the AUC curve (the number and spacing of secondary peaks depends on bile release patterns, intestinal transit, and EHR cycle time); extended effective half-life (drug that would otherwise be cleared by conjugation and biliary excretion is recycled); increased total AUC; clinically important for morphine (morphine-6-glucuronide EHR), ethinylestradiol (OCP — explains some OCP antibiotic interaction concerns), irinotecan (SN-38 EHR causing severe colitis), digoxin (minor contribution), NSAIDs. Options A, C, D, and E all contain fundamental errors about the pathway or mechanism of EHR.

ANSWER: A

Rationale:

Alpha-1-acid glycoprotein (AGP, also called orosomucoid) is the primary plasma binding protein for basic drugs — it preferentially binds cationic, lipophilic molecules through hydrophobic and electrostatic interactions at its single ligand-binding site. Basic drugs with clinically significant AGP binding include: lidocaine (~70%), propranolol (~87%), quinidine (~80%), chlorpromazine (~95%), methadone (~87%), disopyramide (~50%), and tricyclic antidepressants. AGP is a hepatic acute-phase reactant — its plasma concentration increases 2- to 4-fold above baseline during acute stress states including: sepsis, myocardial infarction, surgery, major trauma, burns, malignancy, and inflammatory disorders. This increase in AGP has clinically important pharmacokinetic consequences for AGP-bound basic drugs. Using lidocaine as the paradigm: at baseline, lidocaine is approximately 70% AGP-bound (fu 0.30); during sepsis with AGP elevated 3-fold, lidocaine binding increases and fu falls (to perhaps 0.10–0.15 — only 10–15% free). The clinical complexity: standard lidocaine plasma concentration assays measure TOTAL drug (bound + free); therapeutic ranges (1.5–5 mg/L) are based on total concentration measured in healthy individuals. In sepsis: (1) If total lidocaine concentration is within range, the actual free drug concentration is lower than expected (reduced antiarrhythmic efficacy); (2) If doses are increased to maintain total concentration in range, free drug concentration remains appropriate; (3) As the patient recovers and AGP returns to normal, the elevated total lidocaine (reflecting high protein-bound drug) releases free drug as AGP falls — potentially producing free drug toxicity (CNS: seizures, cardiac: arrhythmia) even though total plasma concentration appears unchanged or even falling. Understanding this AGP-acute phase response is critical for safe lidocaine management in critically ill patients. Option B reverses both the drug type (AGP binds basic, not acidic) and the direction of change (AGP increases, not falls, in sepsis) Option C is partially correct that albumin is a negative acute-phase reactant (it falls in sepsis), but albumin primarily binds acidic drugs, not basic drugs like lidocaine. Option D is incorrect — alpha-2-macroglobulin is not the primary binding protein for lidocaine; AGP is. Option E is incorrect — IgG does not primarily bind lidocaine; immunoglobulins serve immune functions and have minimal pharmacological drug-binding significance.

ANSWER: B

Rationale:

Hemodialysis removes drugs through a semi-permeable membrane by diffusion (driven by concentration gradient between blood and dialysate) and convection (bulk flow of solvent carrying dissolved drug). For dialysis to effectively remove a clinically meaningful amount of drug, two conditions must both be met: (1) The drug must reside in the plasma compartment — dialysis can only remove drug present in the blood flowing through the dialyzer; drug sequestered in peripheral tissues (reflected by large Vd) is inaccessible to the dialyzer membrane; even if dialysis removes all drug from the plasma, drug rapidly redistributes from tissues into plasma (maintaining plasma concentration) — dialysis-induced plasma drug clearance is continuously replenished by tissue redistribution in high-Vd drugs; the practical threshold is Vd < approximately 1 L/kg (70 L in a 70 kg adult) for dialysis to be clinically useful. (2) The drug must be minimally protein-bound — only free (unbound) drug crosses the dialysis membrane; a drug that is 99% protein-bound has fu = 0.01; even if all free drug is removed from plasma during one dialysis pass, the protein-bound 99% remains and re-equilibrates, rapidly regenerating free drug; the effective contribution of dialysis to total body clearance is proportional to fu. Clinically dialyzable drugs (small Vd + low protein binding): lithium (Vd 0.7 L/kg, protein binding < 5% — highly dialyzable; dialysis is standard management for severe lithium toxicity); salicylates (moderate Vd, moderate protein binding — moderately dialyzable; dialysis is indicated for severe salicylate poisoning); ethylene glycol and methanol (low MW, freely water-soluble, low protein binding — highly dialyzable); metformin (low Vd, low protein binding). NOT dialyzable (large Vd and/or high protein binding): digoxin (Vd ~500 L — not effectively dialyzed despite modest protein binding); tricyclic antidepressants (Vd >10 L/kg, high protein binding — dialysis is ineffective); chloroquine (Vd >300 L/kg — not dialyzable). Option A is incorrect — high endogenous clearance makes dialysis supplementation proportionally less impactful, not more; and half-life alone does not determine dialyzability. Option C inverts the relationship — high MW and high protein binding PREVENT dialysis removal, not promote it. Option D is incorrect — renal elimination fraction is not the primary determinant; a renally eliminated drug with large Vd is not effectively dialyzable, while a hepatically eliminated drug with small Vd might be dialyzable. Option E is incorrect — lipophilicity, molecular size, and protein binding all critically affect dialyzability.